Medical/Pharmaceuticals
Zenshine Pharmaceuticals' ZX-7101A Met the Primary Endpoint of the Phase 2 Study for the Treatment of Acute Uncomplicated Influenza in Adults
NANJING, China, April 13, 2023 /PRNewswire/ -- On April 1st, 2023, during the First Infection Collaboration Forum of the Chinese National Center for Infectious Diseases, Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine Pharmaceuticals) announced that its proprietary anti-influenza agent ZX-71...
2023-04-14 01:15
2805
Viva Biotech Attended SAPA-China
HONG KONG, April 12, 2023 /PRNewswire/ -- 6th-7th April, the "2022 SAPA-China Annual Conference - Opportunities and Challenges for the Development ofChina's Biopharmaceutical Industry" hosted by The Sino-American Pharmaceutical Professionals Association (SAPA) was held inChengdu, Sichuan. Viva Bi...
2023-04-13 11:33
2848
Smart Physiotherapy Systems: One-Stop Solution for Pain Patients
WUHAN, China, April 12, 2023 /PRNewswire/ -- Rhein Laser Technologies Ltd., a leading manufacturer of innovative medical lasers for urologic, aesthetic and physiotherapy markets based inWuhan and Dusseldorf, reported the great improvement of Smart Physiotherapy Systems that were launched several ...
2023-04-13 11:10
3188
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis
SEONGNAM, South Korea and CAMBRIDGE, Mass., April 12, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis, cancer, and inflammation, announced it has dosed the first patient in its Phase 2a clinical study...
2023-04-13 06:00
2917
Standigm announces Younsung Choo as chief executive officer
Former LG life Sciences exec and long-time Standigm advisor brings extensive
experience in pharmaceuticals and project management
SEOUL, South Korea, April 12, 2023 /PRNewswire/ -- Standigm
2023-04-13 00:07
2866
Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibody in Australia and Southeast Asia
SINGAPORE, April 11, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with CTTQ-Akeso ( Shanghai) Biomed. Tech. Co., Ltd. (CTTQ-Akeso)（jointly established by Akeso, Inc. (9926.HK, Akeso) and Chia Tai Tianqing Pharmaceutical Group Co...
2023-04-12 06:00
3379
Lunit Demonstrates Progress in the Development of Novel Diagnostics at the 2023 AACR Annual Meeting
* Lunit and collaborators demonstrate key progress in the development of novel diagnostics for cancer therapies, including immuno-oncology, in addition to molecular targeted agents and antibody-drug conjugates * Presentations to deliver new research using Lunit SCOPE in a wide range of cancer...
2023-04-11 21:00
3019
OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its CDH6 ADC at AACR Annual Meeting 2023
NEW YORK, April 11, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that the preclinical data on its lead program CUSP0...
2023-04-11 20:00
1995
SK Biopharmaceuticals Wins Red Dot Design Award for Wearable Devices
* 'Zero WiredTM' and 'Zero EarbudsTM' named 'Winners' in the healthcare category for outstanding product design * SK Biopharmaceuticals' wearable devices earn a global accolade once again following the CES® Innovation Awards SEOUL, South Korea, April 10, 2023 /PRNewswire/ -- SK Biopharmaceuti...
2023-04-11 08:00
2921
Asieris' subsidiary makes significant progress in its commercialization strategy by obtaining the "Drug Distribution License"
SHANGHAI, April 10, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its subsidiary, Hainan Yahong ph...
2023-04-10 20:18
2827
GC Genome Announces Publication Demonstrating Feasibility of Liquid Biopsy Technology to Predict Radiation Therapy Response in Solid Tumors
YONGIN, South Korea, April 9, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a new study in Radiation Oncology Journal,which demonstrates the feasibility of cell-free DNA(cfDNA) monitoring to predict treatment response and detect min...
2023-04-10 11:39
2152
China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released
SHANGHAI, April 6, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset (R&D code: 9MW2821) demonstrated promising clinical data. The preliminary data show positive therapeut...
2023-04-07 16:34
5177
Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD")
SHANGHAI, April 6, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel solution Ensifentrine in mainlandChina. Ensifentrine is a fi...
2023-04-07 10:00
2959
AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering
NEW YORK, April 6, 2023 /PRNewswire/-- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platfo...
2023-04-07 07:15
5293
Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio
CAMBRIDGE, Mass., April 5, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND" (I to I™ ), announced today it has entered into a collaboration agreement wi...
2023-04-06 10:20
3323
BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer
CAMBRIDGE, Mass. and DAEJEON, South Korea, April 5, 2023 /PRNewswire/ --
BIORCHESTRA
2023-04-05 20:00
3385
Standigm and Institut Pasteur Korea Identify Lead Compounds for Resistant Tuberculosis Thanks to Right Foundation Grant
Research achievements enabled by a combination of advanced AI platforms,
research capabilities, and drug discovery technologies
SEOUL, South Korea, April 4, 2023 /PRNewswire/ -- Standigm
2023-04-05 00:07
3337
Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis
NEWARK, Del. and NANJING, China, April 4, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced that it has successfully opened an IND following review by the U.S. Food and Drug Administration toinitiate a Phase 2 clinical trial of BS...
2023-04-04 20:50
2637
Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects
HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has recently completed phase I trials in healthy subjects inChina for its self-developed innovative intestina...
2023-04-04 20:00
3468
iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.
* Secured the effectiveness confirming data of PHAGERIA® technology for colorectal cancer organoids * The first target cancer type of PHAGERIA® technology is colorectal cancer (CRC) BOSTON and SEOUL, South Korea, April 3, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON",www.intodeworld.com...
2023-04-04 10:33
3100
Week's Top Stories
Most Reposted
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
OGA 2026 OPENS WITH STRONGER FOCUS ON MARKET ACCESS, REGIONAL PROJECTS AND ENERGY OPPORTUNITIES
[Picked up by 276 media titles]
2026-09-04 01:35
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
[Picked up by 266 media titles]
2026-09-07 13:00
People See One Brand. The Internet May Show Them Hundreds More.
[Picked up by 264 media titles]
2026-09-07 09:00Most Read
FinVolution and NUS Business School share project findings focusing on Financial Inclusion for Filipino Overseas Domestic Helpers at UN Global Compact BRI Summit
2026-09-04 13:11
12205
Physical AI Firm XTEND Set to Make NYSE Trading Debut: NYSE Content Update
2026-09-04 21:14
11326
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
2026-09-04 10:43
8838
DAHON TECH Announces 2026 Interim Results; Revenue and Profit Record Strong Growth
2026-09-04 16:09
8508